semaglutide mastery course
Unit 5 of 12

cardiovascular outcomes

SELECT trial data, MACE endpoints, and the cardioprotective evidence.

beyond glycemic control

This unit covers the landmark SELECT trial that demonstrated a 20% reduction in major adverse cardiovascular events in 17,604 patients without diabetes, the proposed mechanisms linking GLP-1 receptor agonism to cardiovascular protection including anti-inflammatory pathways, and the clinical implications for patients with established atherosclerotic cardiovascular disease.

Interactive Trial Data

Explore SELECT trial MACE outcomes and event curves.

SELECT trial MACE reduction chart
17,604
adults enrolled in SELECT -- the largest cardiovascular outcome trial for any GLP-1 receptor agonist, with established atherosclerotic disease
20%
reduction in 3-point MACE (HR 0.80) -- cardiovascular death, non-fatal MI, or non-fatal stroke vs placebo
HR 0.72
non-fatal myocardial infarction hazard ratio -- a 28% reduction that was the strongest individual MACE component
9.4%
mean weight loss in SELECT -- participants were not selected for weight loss, making this a secondary observation in a CV outcome trial
correlation vs mechanism. SELECT demonstrated that semaglutide reduces MACE events, but whether the benefit comes from weight loss, direct anti-inflammatory effects on atherosclerotic plaques, metabolic improvements, or some combination remains an open question. The benefit emerged within 12-18 months -- faster than weight-mediated effects would predict -- which suggests at least some weight-independent mechanism.

key terms for this unit

M MACE (major adverse cardiovascular events) trial endpoints
The standard composite endpoint in cardiovascular outcome trials: cardiovascular death, non-fatal myocardial infarction, and non-fatal stroke. SELECT used this 3-point MACE as its primary endpoint, showing a hazard ratio of 0.80 (95% CI 0.72-0.90). Individual components were also reported, with non-fatal MI showing the strongest signal at HR 0.72.
H hazard ratio biostatistics
A measure of the relative rate of events between treatment and control groups over time. An HR of 0.80 means the semaglutide group experienced MACE events at 80% the rate of the placebo group. The 95% confidence interval (0.72-0.90) not crossing 1.0 confirms statistical significance. For context, the earlier SUSTAIN 6 diabetes trial showed HR 0.74 for MACE.
A atherosclerotic cardiovascular disease cardiology
SELECT enrolled adults with overweight/obesity and established atherosclerotic disease but without diabetes -- a population not previously studied with GLP-1 RAs. This was significant because prior CV outcome trials (SUSTAIN 6, LEADER) only enrolled people with diabetes, leaving open whether the benefit was glucose-dependent. SELECT proved it was not.
H HFpEF (heart failure with preserved ejection fraction) emerging evidence
The STEP-HFpEF trial demonstrated that semaglutide improved symptoms, physical function, and reduced body weight in patients with obesity-related HFpEF. This is notable because HFpEF has few effective treatments, and the benefit appeared to extend beyond simple weight reduction to include improvements in cardiac structure and function.
C CRP reduction inflammation
C-reactive protein, a systemic inflammation marker, drops substantially with semaglutide treatment. Since inflammation drives atherosclerotic plaque progression and rupture, CRP reduction is one proposed mechanism for the cardiovascular benefit. The fact that the MACE benefit appeared within 12-18 months supports an anti-inflammatory pathway beyond slow weight-mediated vascular remodeling.

the March 2024 label expansion

SELECT's results were strong enough for the FDA to expand the Wegovy label in March 2024 to include cardiovascular risk reduction in adults with established atherosclerotic disease and overweight/obesity. this was a landmark: the first time an anti-obesity medication received a cardiovascular indication. the 20% MACE reduction (HR 0.80) in 17,604 patients without diabetes established that GLP-1R agonism has cardiovascular benefits independent of glucose control.

The timing of benefit is perhaps the most scientifically interesting finding. the event curves began separating within 12-18 months, which is faster than you would expect from weight loss alone (vascular remodeling from weight reduction typically takes years). this early separation, combined with the CRP reduction data and the non-fatal MI signal (HR 0.72, a 28% reduction), suggests direct anti-inflammatory or anti-atherosclerotic effects of GLP-1R activation on vascular tissue. the STEP-HFpEF data adds another dimension, showing that the cardiac benefits extend to heart failure phenotypes where obesity drives diastolic dysfunction.